Colorectal cancer is the third most common cancer worldwide, with nearly 1.4 million new cases diagnosed in 2012. It is also one of the most common cancers in China, with nearly 200,000 people dying annually as a result of colorectal cancer. Prediction and intervention of colorectal cancer risk would save millions of lives worldwide. The purpose of this study is to provide a simple, effective and economic method to help people predict and intervene in colorectal cancer risk.
A total of 720182 subjects including 18406 colorectal cancer patients and 701776 normal people (see the table for details) were involved in the study. The data were used in the study including demographic, CBC, CMP, lipids and urinalysis data. Analysis of covariance, logistic analysis and discriminant analysis were used to identify the significant factors and to build the colorectal cancer risk prediction model and the significant level was set at p < 0.05. SAS was used as the primary statistical analysis tool.Table: 12P
Subject by gender
|Male||Female||Total||% of Males||Male||Female||Total||% of Males|
|Colorectal cancer patients||8,002||5,224||13,226||60.5%||3,115||2,065||5,180||60.1%|
The analysis showed that CBC, CMP, lipids and urinalysis data can significantly distinguish healthy individuals from colorectal cancer patients and those data can be used to build colorectal cancer risk prediction models. The predicting accuracy was 96.1% and the clinical verification rate was 95.7%. Top parameters were selected through the discriminant analysis and logistic analysis. Some parameters, such as red cell distribution width, red cell count, leukocyte percentage and age are positively correlated with colorectal cancer risk, and others, such as albumin, platelet count, hematocrit and platelet distribution width are negatively correlated with colorectal cancer risk.
This research shows that the routine blood and urine test results can be used to predict colorectal cancer risks and the accuracy of the prediction is over 95%. The research would provide an effective, convenient and economical method to help people predict and intervene in colorectal cancer risk.
Clinical trial identification
Legal entity responsible for the study
Fuyang No2. Hospital and Beijing Yiwang Data Technology.
Has not received any funding.
All authors have declared no conflicts of interest.